Coronavirus / COVID

A new survey shows parents’ fears of getting kids to their providers for fear of contracting the virus.

US government has purchased this batch of vaccines, which Moderna will manufacture concurrently with its phase 3 trials.

A look at the processes and clinical practices at place to assure candidate safety during the COVID-19 vaccine race.

How can we bridge the divide between the public and public health? Raj Bhopal argues for a strong but supportive pandemic response.

The pharmaceutical industry plays an essential role in advancing antimicrobial stewardship and addressing the growing threat of resistant pathogens.

David Ho, MD, likens and contrasts the pandemic to 3 other viral outbreaks and their respective responses.

The modified adenovirus-strain candidate did not reach phase 3 assessment, and was criticized by the WHO for being rushed through assessment.

A backlog in testing in the US can severely impact the ability to perform contact tracing.

The antiviral is currently emergency authorized for treatment of severe COVID-19.

A breakdown of how COVID-19 infection was not managed well in hospitals and ICUs early on.

The clearance for the phase 2 preventive trial will seek the oral antiviral's benefit in elderly care facilities.

The authorization is for an amplicon-based next-generation sequencing test from Helix.

New joint data from the American Academy of Pediatrics and Children's Hospital Association shows 3 states make up one-fourth of all pediatric cases.

The island country of 5 million declared the pandemic over in approximately 100 days. A team of clinicians explain the decision-making and rationale which drove their successes.

A Harvard professor and study author discusses new findings showing the heightened risk of healthcare worker infection.

The FDA has continued taking various hand sanitizers contaminated with methanol off the market.

Raj Bhopal, BSc MD, MPH, addresses the nuances of competing ethical priorities societies face amid COVID-19, alongside political battles and terms like “herd immunity.”

David Ho, MD, shares insight into the public and scientific health shortcomings which burdened the nation back in March.

RLF-100 is an investigational therapy granted an FDA IND this week and looks to treat moderate and severe cases of COVID-19.

A study suggests that both have similar cycle thresholds but the virus lays dormat in an overwhelming majority of asymptomatic patients.

A recent increase in stress cardiomyopathy (Takotsubo Syndrome) could reflect the severe psychosocial pressures of the COVID-19 pandemic.

Patrick Soon-Shiong and Dr. Adam Brufsky have an open minded discussion on the dangers and potential lessons of the course Swedish health officials recommended the country take over the SARS-CoV-2 pandemic.

Will screening be based on symptoms alone? How accurate and fast must tests be?

The letter was penned by IDSA President Thomas M. File, Jr., MD, MSc, FIDSA and HIVMA Chair Judith Feinberg, MD, FIDSA on behalf of their organizations.

Investigational therapy, RLF-100, is being studied with the goal of preventing progression to respiratory failure.

Peter Hotez, MD, PhD, discusses the need to take a grounded approach when discussing plans for the introduction of vaccine immunity against COVID-19.

This finding suggests large disparities in kids and echoes adult population positive rates.

BARDA is committing over $1 billion for the agreement, which is dependent on approval or emergency use authorization by the US FDA.

The Novavax NVX-CoV2373 vaccine candidate is shown to be well-tolerated and elicited antibody response.